Previous 10 | Next 10 |
Enrollment ongoing for AL001 INFRONT-3 Phase 3 trial in frontotemporal dementia with a progranulin mutation and for AL002 INVOKE-2 Phase 2 trial in early Alzheimer’s disease patients Three abstracts accepted for presentation at 2021 Alzheimer’s Association Inte...
An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participat...
Shares of Alector (ALEC) are up 18.1% to $21.18 after the U.S. Patent and Trademark office yesterday published the company's patent application for its anti-MS4A4A program used to develop Alzheimer's disease treatments.The application, which was filed on April 20, 2020, is for the u...
Gainers: Clovis Oncology (CLVS) +43%, Marker Therapeutics (MRKR) +23%, Alector (ALEC) +17%, Aravive (ARAV) +14%, Ortho Clinical Diagnostics (OCDX) +8%.Losers: Idera Pharmaceuticals (IDRA) -62%, Praxis Precision Medicines (PRAX) -13%, Acu...
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participat...
Alector (ALEC): Q4 GAAP EPS of -$0.66 misses by $0.02.Revenue of $4.85M (-19.2% Y/Y) misses by $3.48M.Press Release For further details see: Alector EPS misses by $0.02, misses on revenue
Continued execution across broad immuno-neurology portfolio, multiple milestones expected in 2021 Initiated AL001 INFRONT-3 Phase 3 trial in people with frontotemporal dementia with a progranulin mutation; pipeline expansion to ALS planned for 2021 Initiated AL00...
The first participant has been dosed in Alector's (ALEC) INVOKE-2, a Phase 2 clinical study evaluating the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer’s disease. The Phase 2 study will enroll approx. 265 participants. The primary endp...
AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study will enroll early Alzheimer’s disease patients at up to 90 sites globally Alzheimer’s disease is a devastating neurological disease affecting nearly six million peopl...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...